Polymers for reversing heparin-based anticoagulation

US10111902B2 · US · B2

Patent metadata
FieldValue
Publication numberUS-10111902-B2
Application numberUS-201514629408-A
CountryUS
Kind codeB2
Filing dateFeb 23, 2015
Priority dateJun 1, 2011
Publication dateOct 30, 2018
Grant dateOct 30, 2018

How to read this patent

A practical reading order for non-experts. Skip the full description unless you need deep technical detail.

  1. Title

    What the patent document calls the invention.

  2. Abstract

    A short plain-language summary of the technical disclosure.

  3. Assignees and inventors

    Who owns or filed the patent and who is credited as inventor.

  4. Key dates

    Filing, priority, publication, and grant dates set the timeline.

  5. First independent claim

    The legal scope of protection — read this for what is actually claimed.

  6. CPC / IPC classifications

    Technology tags used to group this patent with similar filings.

  7. Citations and related patents

    Prior art links and similar publications in this corpus.

Abstract

Official abstract text for this publication.

Embodiments presented herein relate to various polymers. Some of the polymer embodiments are heparin binding polymers. Some embodiments of the heparin binding polymers can be employed to bind to heparin for methods such as separating, purifying, removing, and/or isolating heparin and heparin like molecules.

First claim

Opening claim text (preview).

The invention claimed is: 1. A controlled release delivery device comprising: a support having a surface; a heparin binding polymer attached to the surface, the heparin binding polymer comprising: a first dendritic polyol; one or more cationic moieties, at least one of the one or more cationic moieties attached to the first dendritic polyol; and at least one cleavage site; and heparin bound to the heparin binding polymer, wherein the heparin binding polymer has the structure of Formula (I): wherein L1, L2, L3, L4 and L5 comprise dendritic polyols. 2. The controlled release delivery device of claim 1 , wherein the surface forms part of a bead. 3. The controlled release delivery device of claim 1 , wherein the surface comprises a flat surface. 4. The controlled release delivery device of claim 1 , wherein the surface forms at least a portion of a cartridge. 5. The controlled release delivery device of claim 1 , wherein the heparin binding polymer is attached to the surface via an acetal bond or a ketal bond. 6. The controlled release delivery device of claim 1 , wherein the heparin binding polymer is attached to the surface via a disulfide bond. 7. The controlled release delivery device of claim 1 , wherein the heparin binding polymer comprises a protective moiety covalently attached to the first dendritic polyol. 8. The controlled release delivery device of claim 1 , wherein the heparin binding polymer comprises a second dendritic polyol, wherein the at least one cleavage site links the first dendritic polyol to the second dendritic polyol. 9. A controlled release delivery device comprising: a support having a surface; a heparin binding polymer attached to the surface, the heparin binding polymer comprising: a first dendritic polyol; one or more cationic moieties, at least one of the one or more cationic moieties attached to the first dendritic polyol; and at least one cleavage site; and heparin bound to the heparin binding polymer, wherein the heparin binding polymer has the structure of Formula (II): wherein L1, L2, L3, and L4 comprise dendritic polyols. 10. The controlled release delivery device of claim 9 , wherein the surface forms part of a bead. 11. The controlled release delivery device of claim 9 , wherein the surface comprises a flat surface. 12. The controlled release delivery device of claim 9 , wherein the surface forms at least a portion of a cartridge. 13. The controlled release delivery device of claim 9 , wherein the heparin binding polymer is attached to the surface via an acetal bond or a ketal bond. 14. The controlled release delivery device of claim 9 , wherein the heparin binding polymer comprises a protective moiety covalently attached to the first dendritic polyol. 15. The controlled release delivery device of claim 9 , wherein the heparin binding polymer comprises a second dendritic polyol, wherein the at least one cleavage site links the first dendritic polyol to the second dendritic polyol.

Assignees

Inventors

Classifications

  • Polymers containing nitrogen · CPC title

  • Blood · CPC title

  • Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers (A61K47/10 takes precedence) · CPC title

  • Polyalkylene oxides · CPC title

  • Polyamines containing oxygen in the form of ether bonds in the main chain · CPC title

Patent family

Related publications grouped by family.

External sources

Frequently asked questions

Answers are generated from the same data shown on this page.

What does patent US10111902B2 cover?
Embodiments presented herein relate to various polymers. Some of the polymer embodiments are heparin binding polymers. Some embodiments of the heparin binding polymers can be employed to bind to heparin for methods such as separating, purifying, removing, and/or isolating heparin and heparin like molecules.
Who is the assignee on this patent?
Univ British Columbia
What technology area does this patent fall under?
Primary CPC classification A61K31/795. Mapped technology areas include Human Necessities.
When was this patent published?
Publication date Tue Oct 30 2018 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
What related patents are in patentsdb?
We list 2 related publications on this page (citations in our corpus or others sharing the same primary CPC).